Coeptis Therapeutics Surges 21% in Volatile Intraday Session—What's Fueling the Momentum?

Summary
• Coeptis Therapeutics (COEP) rockets 21.08% to $13.90, hitting a 52-week high of $14.46
• 15-minute chart signals overbought RSI and bearish Marubozu patterns
• Turnover surges to 105,949 shares, 3.51% of float

COEP’s explosive intraday rally has ignited market speculation, with the stock trading at its highest level since May 2024. The sharp move follows conflicting technical signals—overbought momentum indicators and bearish candlestick patterns—raising questions about sustainability. With the biotech sector grappling with regulatory delays and layoffs, COEP’s performance stands apart as a high-volatility outlier.

Technical Overbought Conditions Trigger Reversal Signals
Coeptis Therapeutics’ 21% intraday surge has triggered overbought RSI conditions on its 15-minute chart, while bearish Marubozu patterns and a KDJ death cross at 09:45 ET suggest imminent downward pressure. The stock’s rapid ascent—exceeding its 52-week high—has outpaced fundamental support, creating a technical divergence. Sellers now dominate as the death cross confirms a shift in momentum, with the Marubozu’s long upper shadow signaling rejection of higher prices. This confluence of bearish signals indicates a high probability of a pullback, despite the short-term euphoria.

Navigating COEP’s Volatility: ETFs and Technical Levels
• MACD: 0.3957 (bullish) vs. Signal Line: 0.4809 (bearish), Histogram: -0.0852 (divergence)
• RSI: 48.63 (neutral, not overbought)
• Bollinger Bands: Upper $12.16 (below current price), Middle $11.18, Lower $10.20
• 200-day MA: $7.64 (far below current price)
• Support/Resistance: Key support at $11.26, resistance at $11.91

COEP’s technical profile reveals a short-term bullish trend but a long-term divergence. The stock is trading above its 200-day MA and Bollinger Upper Band, suggesting overbought conditions. However, the RSI remains in neutral territory, avoiding immediate overbought territory. Traders should monitor the $11.26 support level, where accumulated volume provides a potential buying opportunity. The absence of options liquidity shifts focus to ETFs like the iShares Biotechnology ETF (IBB) for sector exposure, though no leveraged ETFs are available. A breakout above $14.46 could extend the rally, but the bearish Marubozu and death cross warrant caution. Aggressive bulls may consider a long position into a pullback, targeting $11.26 as a key entry, with a stop-loss below $10.96.

Backtest Coeptis Therapeutics Stock Performance
The COEP experienced a 21% intraday surge on August 15, 2025, and subsequent backtests show mixed short-term performance. The 3-day win rate is 47.70%, the 10-day win rate is 43.09%, and the 30-day win rate is 46.38%. While the COEP had positive returns in the short term, the maximum return during the backtest period was only 5.48%, which occurred on day 59 after the surge.

Act Now: COEP at Crossroads of Bullish Momentum and Bearish Signals
Coeptis Therapeutics’ 21% surge has created a technical crossroads, with overbought indicators clashing against a bearish death cross. While the stock’s short-term trend remains bullish, the divergence in momentum metrics suggests a potential reversal. Investors should closely watch the $11.26 support level and the sector leader Amgen (AMGN), which rose 1.96% today. A breakdown below $11.26 could trigger a sharp correction, while a sustained move above $14.46 would validate the bullish case. Position sizing and stop-loss placement are critical given the high volatility. For now, the market is betting on a continuation of the rally, but the bearish technicals demand vigilance.